Differential Induction of ARIA-like Pathologies by Anti-Aβ Immunotherapies in 5XFAD Mice: A Comprehensive Analysis of 12-Weeks Dosing with Clinical-Stage Antibodies (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR304.17 / U26; Pres time: Nov 18, 2026; 08:00 AM - 12:00 PM; Location: WCC Halls A-C; " We treated 8-month-old 5XFAD mice (n=5-10 group) for 12 weeks with weekly (QW) intraperitoneal injections of: 1) Isotype-mIgG2 control, 2) 3D6-mIgG2 (murine precursor of bapineuzumab), 3) Aducanumab-mIgG2 (humanized), or 4) Remternetug-mIgG2 (humanized). This head-to-head study in a robust amyloidosis model demonstrates that the risk of inducing ARIA-like pathology is highly dependent on the specific antibody's properties. These preclinical findings provide critical mechanistic insights into ARIA pathogenesis and underscore the importance of antibody screening for mitigating treatment-emergent adverse events."
Preclinical • Alzheimer's Disease • CNS Disorders
|